Definium Therapeutics, Inc. (DFTX) - Total Liabilities
Based on the latest financial reports, Definium Therapeutics, Inc. (DFTX) has total liabilities worth $107.77 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Definium Therapeutics, Inc. to track the company's year-over-year net asset growth rate.
Definium Therapeutics, Inc. - Total Liabilities Trend (2015–2025)
This chart illustrates how Definium Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Definium Therapeutics, Inc. (DFTX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Definium Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Definium Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cisarua Mountain Dairy Tbk PT
JK:CMRY
|
Indonesia | Rp2.14 Trillion |
|
Aker Solutions ASA
OL:AKSO
|
Norway | Nkr25.82 Billion |
|
Sumec Corp Ltd
SHG:600710
|
China | CN¥46.13 Billion |
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
Israel | ILA1.82 Billion |
|
Basic Fit NV
AS:BFIT
|
Netherlands | €3.56 Billion |
|
Computer Age Management Services Limited
NSE:CAMS
|
India | Rs4.90 Billion |
|
Construcciones y Auxiliar de Ferrocarriles S.A.
MC:CAF
|
Spain | €4.55 Billion |
|
Afi Properties Ltd
TA:AFPR
|
Israel | ILA15.31 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Definium Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Definium Therapeutics, Inc. (DFTX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Definium Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Definium Therapeutics, Inc. (2015–2025)
The table below shows the annual total liabilities of Definium Therapeutics, Inc. from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $107.77 Million | +77.54% |
| 2024-12-31 | $60.70 Million | +30.81% |
| 2023-12-31 | $46.41 Million | +143.27% |
| 2022-12-31 | $19.08 Million | +54.61% |
| 2021-12-31 | $12.34 Million | +118.33% |
| 2020-12-31 | $5.65 Million | +2740.31% |
| 2019-12-31 | $198.96K | +2317.58% |
| 2018-12-31 | $8.23K | -89.77% |
| 2017-12-31 | $80.44K | +6.59% |
| 2016-12-31 | $75.47K | +908.28% |
| 2015-12-31 | $7.49K | -- |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a cli… Read more